sunitinib

Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that inhibits VEGFR2 and PDGFRβ (IC50=80/2 nM). It exhibits antitumor activity and is used for treating kidney cancer and gastrointestinal tumors.

Sunitinib Malate (Sunitinib) is an indolinone-based tyrosine kinase inhibitor. It blocks the tyrosine kinase activities of VEGFR2, PDGFRβ (IC50: 80/2 nM), and c-kit.

Elacridar (GG918) is a potent inhibitor of P-glycoprotein and BCRP.

Sunitinib-D10 is a deuterium labeled Sunitinib. Sunitinib (T0374L) is a inhibitor of multi-targeted receptor tyrosine kinase (IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively).

MC-Val-Cit-PAB-Sunitinib is a conjugate composed of the payload Sunitinib and a linker. It is utilized in the synthesis of HR97-Sunitinib.

Sunitinib (SU 11248) glucuronate is a multi-target receptor tyrosine kinase inhibitor with IC50 values of 80 nM for VEGFR2 and 2 nM for PDGFRβ. As an ATP-competitive inhibitor, it effectively suppresses Ire1α phosphorylation by inhibiting autophosphorylation and subsequent RNase activation.

Sunitinib-platinum(IV) prodrug-1 (Complex A) is a Cisplatin-based Pt(IV) prodrug designed to be reduced to active Pt(II) in intracellular reductive conditions, while concurrently releasing a sunitinib derivative with tyrosine kinase inhibitor (TKI) activity. This compound exhibits remarkable cytotoxicity against renal cell carcinoma (RCC), inducing DNA crosslinking and apoptosis. It inhibits VEGFR/PDGFR signaling pathways, thereby suppressing tumor growth and angiogenesis, and can be used for studying RCC.

2-Formyl sunitinib (1-CHO) is a metabolite of the tyrosine kinase inhibitor, Sunitinib. It is applicable in cancer research.

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid is a sunitinib impurity.

Sunitinib-D4 is a deuterated compound of Sunitinib (TMSM-3447).

Sunitinib-D4 (Standard) is a reference standard of Sunitinib-D4 intended for quantitative analysis, quality control, and related biochemical research applications. Sunitinib-d4 is a deuterated compound of Sunitinib.

Sunitinib impurity 28 is an impurity of Sunitinib.

Sunitinib impurity 61 (Compound 5h) serves as an intermediate. It is either a synthetic intermediate or an impurity of Sunitinib, useful as a reference standard for purity analysis and quality control.

N-Desethyl Sunitinib (SU012662) is the primary active metabolite of Sunitinib produced by the metabolism of cytochrome P450 enzyme 3A4 (CYP3A4).Sunitinib is an orally available inhibitor of a number of tyrosine kinases involved in tumor proliferation and angiogenesis, including VEGFR, PDGFR, KIT, and FLT3, and was approved for the treatment of advanced/metastatic renal cell carcinoma (RCC)

N,N-Didesethyl Sunitinib is a potent AMPK inhibitor with IC50 of 393 nM and 141 nM for AMPKα1 and AMPK2,respectively.

N-Desethyl Sunitinib hydrochloride (SU-12662 hydrochloride) is an active metabolite of Sunitinib with potential anti-cancer activity for the study of cancer.

N-Desethyl Sunitinib D5 is a deuterated compound of N-Desethyl Sunitinib. N-Desethyl Sunitinib (SU012662) is the primary active metabolite of Sunitinib produced by the metabolism of cytochrome P450 enzyme 3A4 (CYP3A4).Sunitinib is an orally available inhibitor of a number of tyrosine kinases involved in tumor proliferation and angiogenesis, including VEGFR, PDGFR, KIT, and FLT3, and was approved for the treatment of advanced/metastatic renal cell carcinoma (RCC)

Sunitinib (Standard) is a reference standard for research and analysis in studies involving Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that inhibits VEGFR2 and PDGFRβ (IC50=80/2 nM). Sunitinib has antitumor activity and can be used for the treatment of kidney cancer and gastrointestinal tumors.

N-Desethylsunitinib hydrochloride is a major and pharmacologically active metabolite of sunitinib, which is potent, ATP-competitive VEGFR, PDGFRβ, and KIT inhibitor.

N-Desethylsunitinib hydrochloride (Standard) is a reference standard for research and analysis in studies involving N-Desethylsunitinib hydrochloride. N-Desethylsunitinib hydrochloride is a major and pharmacologically active metabolite of sunitinib, which is potent, ATP-competitive VEGFR, PDGFRβ, and KIT inhibitor.

N-Desethylsunitinib-[D5] Hydrochloride (Standard) is a reference standard of N-Desethylsunitinib-[D5] Hydrochloride intended for quantitative analysis, quality control, and related biochemical research applications.

PHA-782584 is a metabolite of sunitinib.Sunitinib is an orally active, multi-targeted tyrosine kinase inhibitor with anticancer activity .

Thalidomide-NH-C6-NH-Boc is a synthesized E3 ligase ligand-linker conjugate containing a cereblon ligand derived from Thalidomide and a linker used in the synthesis of MI-389 [compound 22], a highly effective phthalimide PROTAC degrader developed from the multi-targeted receptor tyrosine kinase inhibitor sunitinib.

SB02024 is a VPS34 inhibitor. SB02024 activates cGAS-STING signaling and sensitizes tumors to STING agonist. SB02024 blocked autophagy in vitro and reduced xenograft growth of two breast cancer cell lines, MDA-MB-231 and MCF-7, in vivo. Vps34 inhibitor significantly potentiated cytotoxicity of Sunitinib and Erlotinib in MCF-7 and MDA-MB-231 in vitro in monolayer cultures and when grown as multicellular spheroids. Our data suggests that inhibition of autophagy significantly improves sensitivity to Sunitinib and Erlotinib and that Vps34 is a promising therapeutic target for combination strategies in breast cancer.